Corient Private Wealth LLC Grows Holdings in Grifols, S.A. (NASDAQ:GRFS)

Corient Private Wealth LLC increased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 11.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 50,883 shares of the biotechnology company’s stock after purchasing an additional 5,040 shares during the period. Corient Private Wealth LLC’s holdings in Grifols were worth $379,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Grifols during the fourth quarter worth about $28,000. GAMMA Investing LLC lifted its holdings in Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares in the last quarter. Blue Trust Inc. boosted its position in Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in Grifols in the 4th quarter valued at approximately $77,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Grifols in the fourth quarter worth $91,000.

Analysts Set New Price Targets

Separately, Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Stock Down 0.5 %

GRFS stock opened at $7.27 on Monday. The company’s 50 day moving average price is $7.56 and its 200 day moving average price is $8.04. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of 6.21 and a beta of 0.35. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.